Joaquina Celebre Baranda (Joaquina Baranda)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 16

Top Topics

Metastatic Renal Cell Carcinoma

Circulating Tumor

Top Venues

Molecular carcinogenesis

Nature communications

Exploration of targeted anti-tumor therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis 63 (8) (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis 63 (8) (2024)
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis 63 (8) (2024)
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis (2024)
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Celebre Baranda, Antonio Jimeno
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular carcinogenesis 63 (8) (2024)
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Stephen K Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Mohammed Abushukair, Kelly Mulvaney, Andrew K Godwin, Azhar Saeed
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature communications 15 (1) (2024)
Ian M Freed, Anup Kasi, Oluwadamilola Fateru, Mengjia Hu, Phasin Gonzalez, Nyla Weatherington, Harsh Pathak, Stephen Hyter, Weijing Sun, Raed Al-Rajabi, Joaquina Celebre Baranda, Mateusz L Hupert, Prabhakar Chalise, Andrew K Godwin, Malgorzata A Witek, Steven A Soper
Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. Cells 12 (18) (2023)
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K Williamson, Joaquina Celebre Baranda, Hirva Mamdani, Ya-Li Lee, Nitika Nitika, Li Li, Xingli Wang, Xunwei Dong
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers 15 (9) (2023)
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K Williamson, Joaquina Celebre Baranda, Hirva Mamdani, Ya-Li Lee, Nitika Nitika, Li Li, Xingli Wang, Xunwei Dong
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers 15 (9) (2023)
Stijn Hentzen, Kathan Mehta, Raed Moh'd Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Stephen K Williamson, Weijing Sun, Anup Kasi Loknath Kumar
Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy. Exploration of targeted anti-tumor therapy 4 (3) (2023)